{"mainPropery":{"diseaseId":7295,"diseaseName":"Ovarian cancer","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7295/ovarian-cancer","synonyms":["Ovarian carcinoma"],"synonyms-with-source":[{"name":"Ovarian carcinoma"}],"identifiers":[{"identifierType":"OMIM","identifierId":"167000 "}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":319,"resourceName":"Ovarian Cancer Research Alliance","abbreviation":"","address1":"14 Pennsylvania Plaza, Suite 2110","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10122","country":"United States","phone":"212-268-1002","tty":"","tollFree":"866-399-6262","fax":"202-331-2292","email":"info@ocrahope.org","url":"https://ocrahope.org","freeText":""},{"resourceID":320,"resourceName":"National Ovarian Cancer Coalition","address1":"2501 Oak Lawn Avenue, Suite 435","address2":"","address3":"","address4":"","address5":"","city":"Dallas","state":"TX","zip":"75219 ","country":"United States","phone":"214-273-4200 ","tty":"","tollFree":"888-OVARIAN","fax":"214-273-4201 ","email":"nocc@ovarian.org","url":"http://www.ovarian.org/"},{"resourceID":3366,"resourceName":"Minnesota Ovarian Cancer Alliance","abbreviation":"","address1":"4604 Chicago Ave ","address2":"","address3":"","address4":"","address5":"","city":"Minneapolis","state":"MN","zip":"55407","country":"","phone":"612-822-0500","tty":"","tollFree":"","fax":"","email":"INFO@MNOVARIAN.ORG","url":"http://mnovarian.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/167000 ' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=ovarian%20cancer%5BTIAB%5D%20AND%20%28hasabstract%5Btext%5D%20AND%20%22loattrfree%20full%20text%22%5Bsb%5D%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Ovarian cancer. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Ovarian+cancer%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Ovarian cancer. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/ovarian-cancer' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Ovarian cancer. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1140680/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000889.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/255771-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022260' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/types/ovarian/' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1764,"resourceId":2924,"resourceName":"Mayo Clinic","descriptionText":"The <a href='http://www.mayoclinic.org/diseases-conditions/ovarian-cancer/basics/definition/con-20028096' target='_blank'>Mayo Clinic</a> Web site provides further information on Ovarian cancer.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:167000' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/ovarian-cancer' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":8489,"questionText":"What is ovarian cancer?","answerText":"<strong>Ovarian cancer</strong> is a form of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001289.htm\" target=\"_blank\">cancer</a> that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadically</a> in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be \"hereditary.\" Although the underlying genetic cause of some&nbsp;hereditary&nbsp;cases is unknown, many are part of a hereditary cancer syndrome (such as <a href=\"http://rarediseases.info.nih.gov/gard/12351/brca1-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\">BRCA1</a> or <a href=\"http://rarediseases.info.nih.gov/gard/12352/brca2-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\">BRCA2 hereditary breast and ovarian cancer syndrome</a>, <a href=\"http://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and <a href=\"http://rarediseases.info.nih.gov/gard/7378/peutz-jeghers-polyposis/resources/1\" target=\"_blank\">Peutz-Jeghers syndrome</a>) and are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[8480][8570] The best treatment options for ovarian cancer depend on many factors including the <a href=\"http://www.ovarian.org/types_and_stages.php\" target=\"_blank\">subtype</a> and <a href=\"http://www.cancer.gov/dictionary?CdrID=45885\" target=\"_blank\">stage</a> of the condition, but may include surgery, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>, and/or <a href=\"http://www.cancer.gov/dictionary?CdrID=270742\" target=\"_blank\">targeted therapy</a> (such as <a href=\"http://www.cancer.gov/dictionary?CdrID=46066\" target=\"_blank\">monoclonal antibody</a> therapy).[8575][8576][8577]","dateModified":"2015-03-30T13:39:00"},"basicQuestions":[{"questionId":8480,"questionText":"What are the signs and symptoms of ovarian cancer?","answerText":"Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Some people with ovarian cancer may experience the following:[8570][8571]\r\n<ul>\r\n    <li>Bloating</li>\r\n    <li>Difficulty eating or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003127.htm\" target=\"_blank\">early satiety</a></li>\r\n    <li>Pelvic or lower abdominal pain</li>\r\n    <li>Back pain</li>\r\n    <li>Abnormal <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003156.htm\" target=\"_blank\">vaginal bleeding</a></li>\r\n    <li>Digestive symptoms such as nausea and vomiting; constipation; indigestion; and/or acid reflux</li>\r\n    <li>Weight loss or weight gain</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003140.htm\" target=\"_blank\">Increased urinary frequency or urgency</a></li>\r\n    <li>Tiredness</li>\r\n    <li>Shortness of breath</li>\r\n</ul>","dateModified":"2015-03-27T15:02:00","resourceClassificationName":"Symptoms","references":[{"referenceId":8570,"authors":"Andrew E Green, MD","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"Medscape Reference","date":"November 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/255771-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8571,"authors":"","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"MedlinePlus","date":"October 2013","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000889.htm","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8481,"questionText":"What causes ovarian cancer?","answerText":"Most cases of ovarian cancer occur <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadically</a> in people with little to no family history of the condition. They are due to random changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) that occur only in the cells of the ovary. These mutations (called somatic mutations) accumulate during a person's lifetime and are not inherited or passed on to future generations.[8480]<br />\r\n<br />\r\nHowever, approximately 10-25% of ovarian cancers are thought to be \"hereditary.\" These cases are caused by an <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/predisposition\" target=\"_blank\">inherited predisposition</a> to ovarian cancer that is passed down through a family. In some of these families, the underlying genetic cause is not known. However, many of these cases are part of a hereditary cancer syndrome. For example, the following cancer syndromes are associated with an elevated risk of ovarian cancer and several other types of cancer:[8480]\r\n<ul>\r\n    <li>Hereditary breast and ovarian cancer&nbsp;syndrome&nbsp;due to mutations in the <em><a href=\"http://rarediseases.info.nih.gov/gard/12351/brca1-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\">BRCA1</a></em> or <a href=\"http://rarediseases.info.nih.gov/gard/12352/brca2-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\"><em>BRCA2</em></a> gene is the most common known cause of hereditary ovarian cancer.</li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> is caused by mutations in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\">MLH1</a></em>, <a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\"><em>MSH2</em></a>, <a href=\"http://ghr.nlm.nih.gov/gene/MSH6\" target=\"_blank\"><em>MSH6</em></a>, <a href=\"http://ghr.nlm.nih.gov/gene/PMS2\" target=\"_blank\"><em>PMS2</em></a> or <a href=\"http://ghr.nlm.nih.gov/gene/EPCAM\" target=\"_blank\"><em>EPCAM</em></a> gene</li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/gard/7378/peutz-jeghers-syndrome/resources/1\" target=\"_blank\">Peutz-Jeghers syndrome</a> is caused by mutations in the <em><a href=\"http://ghr.nlm.nih.gov/gene/STK11\" target=\"_blank\">STK11</a></em> gene</li>\r\n</ul>\r\n<br />\r\nOf note, some research suggests that inherited mutations in several other genes (including <a href=\"http://ghr.nlm.nih.gov/gene/BARD1\" target=\"_blank\"><em>BARD1</em></a><em>, <a href=\"http://ghr.nlm.nih.gov/gene/BRIP1\" target=\"_blank\">BRIP1</a>, <a href=\"http://ghr.nlm.nih.gov/gene/MRE11A\" target=\"_blank\">MRE11A</a>, <a href=\"http://ghr.nlm.nih.gov/gene/NBN\" target=\"_blank\">NBN</a>, <a href=\"http://ghr.nlm.nih.gov/gene/RAD51\" target=\"_blank\">RAD51</a>, <a href=\"http://ghr.nlm.nih.gov/gene/RAD50\" target=\"_blank\">RAD50</a>, <a href=\"http://ghr.nlm.nih.gov/gene/CHEK2\" target=\"_blank\">CHEK2</a>, </em>and<em> <a href=\"http://ghr.nlm.nih.gov/gene/PALB2\" target=\"_blank\">PALB2</a></em>) may also be associated with an increased risk for ovarian cancer. However, the risk associated with many of these genes is not well understood. Most are termed \"moderate- or low-penetrant\" genes which means that, on their own, they would be expected to have a relatively small effect on ovarian cancer risk. However, in combination with other genes and/or environmental factors, these genes may lead to a significant risk of ovarian cancer.[8574]","dateModified":"2015-03-27T15:45:00","resourceClassificationName":"Cause","references":[{"referenceId":8480,"authors":"","articleTitle":"Genetics of Breast and Gynecologic Cancers (PDQ®)","bookWebsiteJournalTitle":"National Cancer Institute","date":"2017","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8574,"authors":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM","articleTitle":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","bookWebsiteJournalTitle":"Proc Natl Acad Sci U S A","date":"November 2011","volume":"108(44)","pages":"18032-18037","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8482,"questionText":"Is ovarian cancer inherited?","answerText":"Most cases of ovarian cancer occur <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadically</a> in people with little to no family history of the condition. However, approximately 10-25% of ovarian cancer is thought to be inherited. In some of these families, the underlying genetic cause is not known. However, many of these cases are part of a hereditary cancer syndrome such as <a href=\"http://rarediseases.info.nih.gov/gard/12351/brca1-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\">BRCA1</a> or <a href=\"http://rarediseases.info.nih.gov/gard/12352/brca2-hereditary-breast-and-ovarian-cancer-syndrome/resources/1\" target=\"_blank\">BRCA2 hereditary breast and ovarian cancer syndrome</a>, <a href=\"http://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and <a href=\"http://rarediseases.info.nih.gov/gard/7378/peutz-jeghers-polyposis/resources/1\" target=\"_blank\">Peutz-Jeghers syndrome</a>, which are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[8480] This means that a person only needs a change (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>) in one copy of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell to have a <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/predisposition\" target=\"_blank\">hereditary predisposition</a>&nbsp;to ovarian cancer and other cancers associated with these syndromes. In some cases, an affected person inherits the mutation from an affected parent. Other cases may result from new (<a href=\"http://www.ghr.nlm.nih.gov/glossary=denovomutation\" target=\"_blank\">de novo</a>) mutations in the gene. A person with one of these syndromes has a 50% chance with each pregnancy of passing along the altered gene to his or her child.","dateModified":"2015-03-29T15:34:00","resourceClassificationName":"Inheritance","references":[{"referenceId":8480,"authors":"","articleTitle":"Genetics of Breast and Gynecologic Cancers (PDQ®)","bookWebsiteJournalTitle":"National Cancer Institute","date":"2017","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8485,"questionText":"How is ovarian cancer diagnosed?","answerText":"If ovarian cancer is suspected based on the presence of certain <a href=\"http://rarediseases.info.nih.gov/gard/7295/ovarian-cancer/resources/9\" target=\"_blank\">signs and symptoms</a>, the following tests and procedures may be recommended:[8570][8571]\r\n<ul>\r\n    <li>Physical evaluation and pelvic exam to check for signs of ovarian cancer (i.e. lumps or swelling) and to examine the size, shape and location of the ovaries</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003336.htm\" target=\"_blank\">Ultrasound</a> and other imaging studies to look for abnormal growths </li>\r\n    <li>Blood tests such as a <a href=\"http://www.cancer.gov/dictionary?CdrID=46490\" target=\"_blank\">CA-125 assay</a> which may be elevated in people with ovarian cancer</li>\r\n    <li>A <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003416.htm\" target=\"_blank\">biopsy</a> of the tumor is the only way to confirm a diagnosis of ovarian cancer</li>\r\n</ul>\r\n<br />\r\nThe National Cancer Institute offers more detailed information regarding the tests used to diagnose ovarian cancer. To access this resource, please <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1#_124\" target=\"_blank\">click here</a>.","dateModified":"2015-03-30T10:56:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":8570,"authors":"Andrew E Green, MD","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"Medscape Reference","date":"November 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/255771-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8571,"authors":"","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"MedlinePlus","date":"October 2013","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000889.htm","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8483,"questionText":"How might ovarian cancer be treated?","answerText":"<p>The best treatment options&nbsp;for ovarian cancer depend on many factors including the <a href=\"http://www.ovarian.org/types_and_stages.php\" target=\"_blank\">subtype</a> and&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=45885\" target=\"_blank\">stage</a>&nbsp;of the condition. In general, treatment may include a combination of the following:[8575][8576][8577]</p>\r\n<ul>\r\n    <li>Surgery to remove the ovaries, the fallopian tubes, the uterus, and/or other structures in the belly (pelvis).</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">Radiation therapy</a></li>\r\n    <li><a href=\"http://www.cancer.gov/dictionary?CdrID=270742\" target=\"_blank\">Targeted therapy</a>&nbsp;(such as <a href=\"http://www.cancer.gov/dictionary?CdrID=46066\" target=\"_blank\">monoclonal antibody</a> therapy)</li>\r\n</ul>\r\n<p>Unfortunately, research suggests that there are no benefits&nbsp;of&nbsp;ovarian cancer&nbsp;screening (using a <a href=\"http://www.cancer.gov/dictionary?CdrID=46490\" target=\"_blank\">CA-125</a>&nbsp;blood test&nbsp;and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003779.htm\" target=\"_blank\">transvaginal ultrasound</a>), even&nbsp;in women who are at an elevated risk due to their personal and/or family histories.[8578] Women who are at a high-risk for ovarian cancer may, therefore, want to discuss other preventative measures, such as <a href=\"http://c.merriam-webster.com/medlineplus/prophylactic\" target=\"_blank\">prophylactic</a> surgery,&nbsp;with their healthcare provider. In women with a known hereditary cancer syndrome, management should also&nbsp;include screening for the other component cancers. Please click on the following links for more information regarding the treatment and management of each condition:</p>\r\n<ul>\r\n    <li><a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1247/#brca1.Management\" target=\"_blank\">Hereditary Breast and Ovarian Cancer</a></li>\r\n    <li><a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1211/#hnpcc.Management\" target=\"_blank\">Lynch syndrome</a></li>\r\n    <li><a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1266/#pjs.Management\" target=\"_blank\">Peutz-Jeghers syndrome</a></li>\r\n</ul>\r\n<p>&nbsp;</p>","dateModified":"2015-03-29T15:58:00","resourceClassificationName":"Treatment","references":[{"referenceId":8575,"authors":"","articleTitle":"Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"February 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8576,"authors":"","articleTitle":"Ovarian Germ Cell Tumors Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"March 2014","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarian-germ-cell/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8577,"authors":"","articleTitle":"Ovarian Low Malignant Potential Tumors Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"February 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarian-low-malignant-potential/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8578,"authors":"","articleTitle":"Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening","bookWebsiteJournalTitle":"National Cancer Institute","date":"March 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/screening/ovarian/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8484,"questionText":"What is the long-term outlook for people with ovarian cancer?","answerText":"The long-term outlook (prognosis) for women with ovarian cancer depends on many factors including the <a href=\"http://www.ovarian.org/types_and_stages.php\" target=\"_blank\">subtype</a> of cancer and the <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page2#_136\" target=\"_blank\">stage</a> at which the cancer is diagnosed. In general, <a href=\"http://www.cancer.gov/dictionary?CdrID=45683\" target=\"_blank\">epithelial ovarian cancers</a> (the most common subtype) are often associated with a worse prognosis than more rare subtypes such as <a href=\"http://www.cancer.gov/dictionary?CdrID=45695\" target=\"_blank\">germ cell</a> and <a href=\"http://www.cancer.gov/dictionary?CdrID=44929\" target=\"_blank\">stromal</a> ovarian tumors.[8575][8576][8577] <br />\r\n<br />\r\nBecause early stages of ovarian cancer are often not associated with any specific signs or symptoms, many cases are, unfortunately, diagnosed at a later and less treatable stage. Late stage ovarian cancers are generally associated with a poor prognosis. For example, 5-year survival rates for women diagnosed with stage I ovarian cancer range from 79-87%, while the 5-year survival rates for women diagnosed with stage IV ovarian cancer are approximately 11%.[8570]","dateModified":"2015-03-29T16:33:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8570,"authors":"Andrew E Green, MD","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"Medscape Reference","date":"November 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/255771-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8575,"authors":"","articleTitle":"Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"February 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8576,"authors":"","articleTitle":"Ovarian Germ Cell Tumors Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"March 2014","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarian-germ-cell/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8577,"authors":"","articleTitle":"Ovarian Low Malignant Potential Tumors Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"February 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/ovarian-low-malignant-potential/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13037,"phenoTypeName":"Abnormality of metabolism/homeostasis","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":8875,"phenoTypeName":"Breast carcinoma","percentRanges":"-"},{"phenoTypeId":112,"phenoTypeName":"Dysgerminoma","percentRanges":"-"},{"phenoTypeId":12117,"phenoTypeName":"Ovarian papillary adenocarcinoma","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":24,"genericName":"Doxorubicin HCL liposome","tradeName":"Doxil","tradeLink":"http://www.doxil.com/","manufacturer":"","sponsor":"Alza Corporation","indication":"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens.  Refractory disease is defined as disease that has progressed while on treatment, or within 6 months","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/25316-40-9","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a682221.html"},{"productId":328,"genericName":"Amifostine","tradeName":"Ethyol®","tradeLink":"http://www.ethyol.com/","manufacturer":"","sponsor":"Medimmune Oncology, Inc.","indication":"To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. \r\n\r\n","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Ethyol","medlinePlusLink":""},{"productId":327,"genericName":"Altretamine","tradeName":"Hexalen®","tradeLink":"http://www.eisai.com/pdf_files/hexalen_pi.pdf","manufacturer":"Eisai","sponsor":"Medimmune Oncology, Inc.","indication":"Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Hexalen","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601200.html"},{"productId":616,"genericName":"Olaparib","tradeName":"Lynparza","tradeLink":"http://www.lynparza.com/","manufacturer":"","sponsor":"AstraZeneca Pharmaceuticals LP","indication":"December 2018, olaparib (Lynparza) received expanded approval for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza. Original approval was in August 2017.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/lynparza","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614060.html"},{"productId":137,"genericName":"Satumomab pendetide","tradeName":"Oncoscint CR/OV","tradeLink":"","manufacturer":"","sponsor":"Cytogen Corporation","indication":"For determining the extent and location of extrahepatic malignant disease in patients with known colorectal and ovarian cancer.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/oncoscint%20cr%252Fov","medlinePlusLink":""},{"productId":658,"genericName":"Rucaparib","tradeName":"Rubraca","tradeLink":"https://www.rubraca.com/","manufacturer":"","sponsor":"Clovis Oncology, Inc.","indication":"December 2016 approved as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rubraca","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617002.html"}],"EncodedName":"Ovarian_cancer"}